TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04455438

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT dose escalation
Description: Re-Stereotactic Body Radiation Therapy (SBRT) with increasing dose levels, from 30 Gy in 5 fractions to 50 Gy in 5 fractions.
Study: NCT03521284

Intervention type: OTHER
Intervention: Parental educational program
Description: Behavior: psychotherapy, life hygiene advice

Intervention type: OTHER
Intervention: Questionnaires
Description: knowledge questionnaire + parental anxiety questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: knowledge questionnaire + parental anxiety questionnaire
Study: NCT01669837

Intervention type: DEVICE
Intervention: Mesh fixation with surgical tissue glue
Description: Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
Study: NCT04318873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Promise Demonstration Benefits
Description: Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
Study: NCT03980054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib 400 mg, orally once daily for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 400mg, orally once daily for one year
Study: NCT03638193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-meso cells
Description: CART-meso is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m\^2 of cyclophosphamide, which will be administered according to standard procedures, Thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
Study: NCT00670254

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application is identical to experimental arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
Study: NCT02168244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heating Pack
Description: Application of heat to skin for 2-3 minutes prior to injection of biologic drug

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice pack
Description: Application of cold to skin for 2-3 minutes prior to injection of biologic drug
Study: NCT04053777

Intervention type: DEVICE
Intervention: non-invasive ventilation
Description: Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
Study: NCT01682889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9% intravenously for 24h
Study: NCT03854266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose alteplase
Description: Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion catheter
Description: A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
Study: NCT02318706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02556385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency rTMS
Description: Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency rTMS
Description: Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
Study: NCT03472885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Participants received a daily oral dose of danicopan TID during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Participants received a daily oral dose of danicopan TID during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Participants received a daily oral dose of danicopan TID during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Participants received a daily oral dose of danicopan TID during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Participants received intravenous eculizumab administered at the participant's usual dose and schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Participants received intravenous eculizumab administered at the participant's usual dose and schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Participants received intravenous eculizumab administered at the participant's usual dose and schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
Study: NCT01601236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups \[8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups \[8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups \[8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)\].

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
Study: NCT02937116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\Cisplatinum\Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\cisplatin\gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\oxaliplatin\capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\etoposide\cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\irinotecan\5-FU
Study: NCT03882606

Intervention type: DEVICE
Group type: OTHER
Intervention: Scharioth Macula Lens (SML, Medicontur)
Description: magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient
Study: NCT03079622

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electric Vacuum Aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Vacuum Aspiration
Study: NCT01507259

Intervention type: OTHER
Intervention: cocoa
Description: 70% versus 34%
Study: NCT01074814

Intervention type: DRUG
Group type: OTHER
Intervention: Approved therapy will be assigned based on molecular profile and RPMA results
Description: treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results
Study: NCT03599674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Bridge Program
Description: Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
Study: NCT02066181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Optional ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Optional ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT04455438

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT dose escalation
Description: Re-Stereotactic Body Radiation Therapy (SBRT) with increasing dose levels, from 30 Gy in 5 fractions to 50 Gy in 5 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT dose escalation
Description: Re-Stereotactic Body Radiation Therapy (SBRT) with increasing dose levels, from 30 Gy in 5 fractions to 50 Gy in 5 fractions.
Study: NCT01440712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin
Description: Administration of 100 ml of gastrografin by the nasogastric tube, only once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological serum
Description: Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
Study: NCT04214158

Intervention type: OTHER
Intervention: Assessment
Description: Assessment

Intervention type: OTHER
Intervention: Assessment
Description: Assessment
Study: NCT02175004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotersen
Description: Inotersen SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotersen
Description: Inotersen SC
Study: NCT01208493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preterm infant formula with high protein levels
Description: minimum 3 weeks feeding until hospital discharge
Study: NCT03937570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echo-optimization
Description: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
Study: NCT00224575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnosis reassessment
Description: Strategy of diagnosis reassessment following a decision tree.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnosis strategy and subsequent therapeutic reassessment
Description: Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
Study: NCT00628667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02144610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGF Plasmid (AMG0001)
Description: IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: IM
Study: NCT03408093

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
Study: NCT02558088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Study: NCT01453218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATeGe-Fresenius
Description: Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
Study: NCT01208493

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preterm standard infant formula
Description: minimum 3 weeks feeding until hospital discharge
Study: NCT02038543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyproline and Leucine
Description: Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
Study: NCT02686905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewable Multivitamin with Iron
Description: Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PatchMD Vitamin D3/Calcium Patch
Description: Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PatchMD Multivitamin Patch
Description: Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PatchMD B12 Energy Plus Patch
Description: Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewable Calcium
Description: Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quick Dissolve B12
Description: Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
Study: NCT04242563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIRTUAL REALITY
Description: Patient equipped with virtual reality in transfer room
Study: NCT02179099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTX mixed with TC-3 Gel
Description: Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
Study: NCT03257020

Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.

Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
Study: NCT00655863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and Pioglitazone
Description: Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Study: NCT01450254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy Biomechanical System
Description: The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention will be prescribed to the control group during participation in the study.
Study: NCT00568802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match hydroxyurea
Study: NCT00900744

Intervention type: DRUG
Intervention: Tamoxifen
Description: 20 mg daily
Study: NCT02416804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -\> 10 μg/hr -\> 15 (5+10) μg/hr -\> 20 μg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -\> 200 mg/d -\> 250 mg/d -\> 300 mg/d
Study: NCT04295876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BRIDGES Project Intervention
Description: The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.
Study: NCT02777723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenobella
Description: Hypotonic 0.3% Sodium Hyaluronate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic 0.3% Sodium Hyaluronate
Description: Isotonic 0.3% Sodium Hyaluronate
Study: NCT04262973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: six-hour dementia care course

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education and workshop
Description: six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice